- Clinical Performance Indicates a 40% Reduction of Intraocular Pressure at Two Years -
WALTHAM, Mass., Feb. 19 /PRNewswire/ -- SOLX, Inc. announced today that it has surpassed 1000 implantation procedures with its proprietary SOLX Gold Shunt(R), a drainage device that reduces intraocular pressure (IOP) for the treatment of glaucoma.
"This is a significant milestone," said Doug Adams, President and Founder of SOLX, "as it validates the importance of the Gold Shunt in the treatment of glaucoma. The Gold Shunt provides a more reliable, less invasive surgical alternative in IOP control."
The 1000 patients were treated in the European Union where the device has received CE Mark approval. Entering 2009, over 100 glaucoma surgeons in 20 countries have been certified on Gold Shunt implantation. Clinical results have shown that a significant reduction in IOP of 40% can be maintained for over two years after Gold Shunt implantation while also reducing the patient's need for glaucoma medications by up to half.
"Our patients treated with the Gold Shunt achieved a reduction in IOP which was maintained at clinically beneficial levels for an extended time period," said Modi Goldenfeld, M.D. of the Goldschleger Eye Institute in Tel Hashomer, Israel, and Medical Monitor for an ongoing FDA trial. "One particularly attractive feature of the Gold Shunt is that it utilizes a naturally occurring pressure differential found between the anterior chamber of the eye and the suprachoroidal space which allows the device to reduce IOP without creating a bleb, and thus eliminate bleb related complications."
SOLX is an emerging leader in the management and surgical treatment of glaucoma, a disease of the eye characterized by high intraocular pressure that often leads to optic nerve damage, vision loss and ultimately, blindness.
Additional information can be found at www.solx.com
|SOURCE SOLX, Inc.|
Copyright©2009 PR Newswire.
All rights reserved